Latest News

Study tracks teens on isotretinoin, finding stable cognition but modest rises in depression and anxiety symptoms, reinforcing the need for ongoing mental health monitoring.

FDA granted QRX003 RPD designation for PSS, adding to its Netherton syndrome designation as Quoin prepares for a phase 2 study.

Real-world cohort research links psoriasis biologics to notably fewer heart attacks and strokes over 10 years, with benefits across drug classes and races.

Put your dermatology expertise to the test with Dermatology Times’ interactive quiz series.

Are "clean" skin care routines legitimate, or are they just a myth? Read more about the latest social media trend and learn how to counsel your patients in the clinic.

Clinicians can bridge the gap between online trends and evidence-based outcomes by leveraging patient curiosity, emphasizing ingredient transparency, and delivering personalized in-office care.

AbbVie completed its $10.9 billion Apogee acquisition, adding IL-13 antibody zumilokibart and other inflammatory disease assets.

This review of the latest dermatological studies includes insights on adalimumab durability in HS, medicolegal issues in hair transplantation, yellow light and vitamin C for melasma, and more.

ACP outlines ethical AI in medicine: protect patient trust, fight bias, avoid deskilling, and disclose AI use as dermatology adopts new tools.

Explore the top headlines of the month, including insights on the latest clinical trials, therapeutic updates, and more.

Explore the top dermatology conferences and meetings happening this month and let us know which ones you'll be attending!

Physicians' Education Resource and Dermatology Times debut a dedicated NP/PA education platform and a new congress series, opening with Derm Nexus this November in Scottsdale, Arizona.

A twice-rejected melanoma immunotherapy finally won accelerated approval, acne's decades-long innovation drought moved a step closer to ending, and 2 rare, sun-triggered skin diseases picked up a deep-pocketed new sponsor.